Strategic collaborations are a fantastic way for pharma and biotech companies to collaborate. As the cost of mergers and acquisitions rises, partnering is emerging as the way forward for pharma companies to realise their full potential.
An Alternative is for companies to lead their own European Launch and unlock the great potential of this market, but this is often seen as a difficult market with many complexities to understand.
“Where to launch?” is a question every pharma or biotech company asks when they have a new product, but what is the right answer?
Whilst many companies sensibly opt for the markets they know, there is huge opportunity lying beyond these initial geographies and a market that is not always well understood is Europe.
Europe is a golden opportunity for many pharma and biotech companies but is often seen as a complex environment to enter.
Many US and Asian companies need support to traverse the landscape which comprises EU bodies, Individual regulators and payers, which is where we can help you understand how to unlock the potential in Europe
A great alternative to a European Launch is partnering and strategic collaborations, which can unlock mutual value for all parties.